Citizens Jmp Raises DBV Technologies (NASDAQ:DBVT) Price Target to $55.00

DBV Technologies (NASDAQ:DBVT) had its target price increased by equities researchers at Citizens Jmp from $47.00 to $55.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s target price suggests a potential upside of 242.25% from the stock’s previous close.

Other research analysts have also issued reports about the company. Guggenheim reissued a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research report on Monday, May 4th. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, DBV Technologies presently has an average rating of “Moderate Buy” and an average price target of $48.50.

DBV Technologies Price Performance

Shares of DBVT stock traded up $0.07 on Tuesday, hitting $16.07. 71,803 shares of the stock traded hands, compared to its average volume of 298,517. DBV Technologies has a 52 week low of $8.51 and a 52 week high of $26.18. The firm has a 50 day simple moving average of $18.33 and a two-hundred day simple moving average of $19.86. The firm has a market cap of $951.50 million, a price-to-earnings ratio of -3.60 and a beta of -0.99.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The firm had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. Sell-side analysts forecast that DBV Technologies will post -0.47 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently made changes to their positions in the business. Perceptive Advisors LLC purchased a new position in DBV Technologies during the first quarter worth approximately $20,146,000. Vivo Capital LLC raised its stake in DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after acquiring an additional 205,943 shares during the period. ADAR1 Capital Management LLC acquired a new position in DBV Technologies during the 1st quarter valued at about $21,159,000. Royal Bank of Canada increased its stake in shares of DBV Technologies by 167.1% in the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock valued at $98,000 after purchasing an additional 2,928 shares during the period. Finally, Elmind Capital LP bought a new stake in shares of DBV Technologies during the 1st quarter worth about $5,536,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.